Neovasc Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Neovasc in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Neovasc stock.
View analyst ratings for Neovasc or view top-rated stocks.

1 equities research analysts have issued 12 month price objectives for Neovasc's stock. Their NVCN stock forecasts range from $125.00 to $125.00. On average, they anticipate Neovasc's stock price to reach $125.00 in the next year. This suggests a possible upside of 1,966.1% from the stock's current price.
View analysts' price targets for Neovasc or view top-rated stocks among Wall Street analysts.

Neovasc's stock was trading at $11.7150 at the start of the year. Since then, NVCN stock has decreased by 48.4% and is now trading at $6.05.
View the best growth stocks for 2022 here.

Neovasc is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022.
View our earnings forecast for Neovasc.

Neovasc Inc. (NASDAQ:NVCN) released its quarterly earnings data on Thursday, May, 12th. The medical equipment provider reported ($3.01) EPS for the quarter, missing analysts' consensus estimates of ($1.25) by $1.76. The medical equipment provider earned $0.61 million during the quarter, compared to analyst estimates of $0.80 million. Neovasc had a negative net margin of 1,192.20% and a negative trailing twelve-month return on equity of 50.69%.
View Neovasc's earnings history.

Neovasc's stock reverse split before market open on Friday, April 29th 2022. The 1-25 reverse split was announced on Friday, April 29th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 29th 2022. An investor that had 100 shares of Neovasc stock prior to the reverse split would have 4 shares after the split.

Some companies that are related to Neovasc include Vapotherm (VAPO), Nemaura Medical (NMRD), Pro-Dex (PDEX), Titan Medical (TMDI), Daxor (DXR), TransEnterix (TRXC), Modular Medical (MODD), Biostage (BSTG), Pulse Biosciences (PLSE), Isoray (ISR), Isoray (ISR), SANUWAVE Health (SNWV), GlucoTrack (GCTK), Integrity Applications (IGAP) and enVVeno Medical (NVNO).
View all of NVCN's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Neovasc investors own include Biopharmx (BPMX), Allstate (ALL), Amicus Therapeutics (FOLD), Synergy Pharmaceuticals (SGYP), Rexahn Pharmaceuticals (REXN), Heat Biologics (HTBX), Protalix BioTherapeutics (PLX), Palatin Technologies (PTN), (XXII) and Amarin (AMRN).

Neovasc trades on the NASDAQ under the ticker symbol "NVCN."

Shares of NVCN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NVCN stock can currently be purchased for approximately $6.05.

Neovasc (NASDAQ:NVCN) has a market capitalization of $16.38 million and generates $2.55 million in revenue each year. The medical equipment provider earns $-24,890,000.00 in net income (profit) each year or ($12.00) on an earnings per share basis.

Neovasc employs 49 workers across the globe.

Neovasc's mailing address is Suite 5138 - 13562 Maycrest Way, RICHMOND A1, V6V 2J7. The official website for Neovasc is www.neovasc.com. The medical equipment provider can be reached via phone at (604) 270-4344, via email at investors@neovasc.com, or via fax at 604-270-4384.